Eledon Pharmaceuticals, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Eledon Pharmaceuticals, Inc. (ELDN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $344.00 thousand for the 12-month period ending 2022-12-31, per its 10-K/A filed 2024-08-19.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-08-19
- Eledon Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- Eledon Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $0.00.
- Eledon Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $43.00K.
- Eledon Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $446.00K.
- Eledon Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $344.00K, a 58.30% decline from fiscal 2021.
- Eledon Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $825.00K.
- Eledon Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $489.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $344.00K 10-K/A · filed 2024-08-19 | |||
| 2021-12-31 | $825.00K 10-K · filed 2023-03-30 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-17 | $0.00 derived: sum of 2 quarters · filed 2020-03-17 | $43.00K derived: sum of 3 quarters · filed 2020-03-17 | $489.00K 10-K · filed 2020-03-17 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $43.00K derived: sum of 2 quarters · filed 2019-11-13 | $489.00K 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $489.00K 10-Q · filed 2019-08-13 | ||
| 2019-03-31 | $446.00K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |